Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL238493 | 1.00 | LMNA (0.60) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL1592817 | 0.88 | LMNA (0.64) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL8148335 | 0.81 | CYP19A1 (0.53) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL29445509 | 0.79 | SHBG (0.60) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL6706306 | 0.79 | LMNA (0.58) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL8148330 | 0.78 | CYP19A1 (0.53) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL11722908 | 0.77 | LMNA (0.62) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL10380227 | 0.76 | LMNA (0.74) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL8408550 | 0.76 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL10861103 | 0.76 | LMNA (0.81) | LMNAMAPTCYP19A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3439640-B1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | CLEVELAND CLINIC FOUND (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3471712-B1 | SMALL MOLECULE INHIBITORS OF ALDH AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2024-01-03 | — | — | EP | disclosed |
| US-11013817-B2 | Nanoparticles for drug delivery to treat bone disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| US-20200121703-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION | 2020-04-23 | — | — | US | disclosed |
| EP-3125884-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190307896-A1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | THE CLEVELAND CLINIC FOUNDATION | 2019-10-10 | — | — | US | disclosed |
| WO-2019040724-A1 | SMALL MOLECULE INHIBITORS OF MYC AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-28 | — | — | WO | disclosed |
| EP-2911748-B1 | CANCER STEM CELL VACCINATION AND TREATMENT | UNIV MICHIGAN REGENTS (US) | 2018-03-14 | — | — | EP | disclosed |
| EP-2831067-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2019671-B1 | INTERMEDIATES FOR THE PREPARATION OF BIVALENT SMAC MIMETICS | UNIV MICHIGAN (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-2139490-B1 | DIAZO BICYCLIC SMAC MIMETICS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2014-07-02 | — | — | EP | disclosed |
| EP-2063887-B1 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | UNIV MICHIGAN (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-2141173-B1 | Methods and compositions for the inhibition of gene expression | PRONAI THERAPEUTICS INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | SANOFI (FR) | 2012-11-15 | — | — | US | disclosed |
| US-8216567-B2 | Therapeutic ribonucleases | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| EP-1718767-B1 | COMPOSITIONS FOR TREATING BREAST AND PANCREATIC CANCER | UNIV MICHIGAN (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120003150-A1 | THERAPEUTIC RIBONUCLEASES | QUINTESSENCE BIOSCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2369014-A1 | Compositions and methods for characterizing, regulating, diagnosing and treating cancer | The Regents Of The University Of Michigan Office Of Technology Transfer (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2141173-A1 | Methods and compositions for the inhibition of gene expression | Pronai Therapeutics, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289494-A1 | SPIRO-OXINDOLE MDM2 ANTAGONISTS | TP53, MDM2, TP53BP1 | LMNA 2384/4885MAPT 1458/4885CYP19A1 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.